Causes and consequences of disturbances of cerebral glucose metabolism in sporadic Alzheimer disease: therapeutic implications.
Alzheimer disease is not a single disorder. Etiologically, two different types or even diseases exist: inheritance in 5% to 10% of all Alzheimer cases versus 90% to 95% AD cases whith sporadic origin (SAD). Different susceptibility genes along with adult lifestyle risk-factors- in the case of SAD the risk factor aging- may be assumed to cause the latter disorder. There is evidence that a disturbance in the insulin signal transduction pathway may be a central and early pathophysiologic event in SAD. Both, hypercortisolemia and increased adrenergic activity, in both old age and SAD may render the function of the neuronal insulin receptor vulnerable resulting in a diminished production of ATP. The reduced availability of ATP may damage the function of the endoplasmic reticulum/Golgi apparatus/trans Golgi network generating misfolded and malfolded proteins retained in the cell. In SAD, amyloid precursor protein is found to accumulate intracellularly thus not representing the cause but a driving force in the pathogenesis of SAD. Additionally, both disturbed insulin signaling and reduced ATP forward the hyperphosphorylation of tau protein. Thus, abnormalities in oxidative brain metabolism lead to the formation of two main morphologic hallmarks of SAD: senile plaques and neurofibrillary tangles. Therefore, the therapeutic goal in SAD should be the improvement of the neuronal energy state. Findings from both basic and clinical studies showed that Ginkgo biloba extract (EGb 761) may be appropiate to approach that goal.